GeneVentiv Therapeutics Moves Forward with GENV-HEM Program
GeneVentiv Therapeutics, Inc., a leading biotechnology company focused on developing one-time gene therapies for rare diseases, has reached a significant milestone by engaging in a productive INTERACT meeting with the U.S. Food and Drug Administration (FDA). This meeting centered around their flagship program, GENV-HEM, which is a pioneering gene therapy aimed at treating Hemophilia A, including patients with and without inhibitors.
FDA Meeting Validates Development Strategy
The recent dialogue with the FDA has confirmed a key alignment regarding GeneVentiv's developmental strategy. This includes the planned IND-enabling studies and an in-depth strategy for CMC (Chemistry, Manufacturing, and Controls). Such alignment is crucial as it establishes a clear pathway toward initiating human clinical trials and reflects the FDA's confidence in the innovative approaches being employed by GeneVentiv.
CEO Highlights Regulatory Milestone
Damon Race, the Chief Executive Officer of GeneVentiv Therapeutics, expressed his enthusiasm about the meeting's results, stating, "This positive and constructive meeting with the FDA represents a key regulatory milestone for GeneVentiv. The Agency's confirmation of our IND-enabling development plan further validates the rigor of our scientific and manufacturing approach and provides a clear path toward first-in-human studies." With this reduced regulatory risk, GeneVentiv is now concentrating efforts on ensuring GENV-HEM progresses smoothly towards IND submission readiness.
Focus on Patient Needs
The feedback received underlines the importance of GENV-HEM as a hopeful solution for hemophilia A patients. Dr. Paris Margaritis, the Chief Scientific Officer, emphasized how the therapy has shown promising results in preclinical studies. He stated, "We appreciate the FDA's thoughtful engagement and the opportunity to align early on our development strategy. GENV-HEM has demonstrated robust preclinical activity and the potential to address the unmet needs of hemophilia patients with or without inhibitors through durable endogenous Factor Va expression." This insight showcases GeneVentiv’s commitment to not just advancing science but enhancing patient care in significant ways.
Next Steps for GeneVentiv
Looking ahead, GeneVentiv intends to maintain an open line of communication with regulatory bodies as they push forward with GENV-HEM’s IND-enabling studies. Critical milestones on their agenda include a Pre-IND Meeting and the actual IND submission, both scheduled for the upcoming year. This proactive approach demonstrates the company's dedication to bringing innovative therapies to the patient community.
About GeneVentiv Therapeutics
GeneVentiv Therapeutics is dedicated to developing transformative gene therapies aimed at treating rare and severe diseases. The company’s leading program, GENV-HEM, focuses on an AAV-based gene therapy that expresses an activated Factor V protein. It is designed to be a one-time treatment for patients suffering from hemophilia A, especially those with inhibitors. Another promising program in their pipeline is GENV-002, which leverages dual-vector CRISPR gene-editing technology to target both Infantile and Late Onset Pompe disease. Their mission is to create therapies that have the potential to reach every patient affected by these conditions, ensuring no one is left behind.
Contact Information
Damon Race
Phone: 919-529-3352
Frequently Asked Questions
What is GeneVentiv Therapeutics known for?
GeneVentiv Therapeutics is recognized for its advancements in one-time gene therapies targeting rare diseases, especially in hemophilia.
What therapy is GeneVentiv developing for Hemophilia A?
GeneVentiv is developing GENV-HEM, which is a gene therapy designed to provide a one-time treatment solution for Hemophilia A patients.
What regulatory achievement did GeneVentiv recently secure?
GeneVentiv successfully held an INTERACT meeting with the FDA, receiving positive feedback on their developmental plan for the GENV-HEM therapy.
How does GENV-HEM address patient needs?
GENV-HEM aims to provide a durable treatment solution that addresses the needs of patients with Hemophilia A, including those with inhibitors.
What are the next steps for GeneVentiv?
GeneVentiv plans to proceed with IND-enabling studies and has scheduled a Pre-IND Meeting and an IND submission for the following year.
